Andropause Support Protocol

Overview

"Andropause" is a colloquial term for the gradual age-related decline in testosterone and supporting endocrine function in men. Unlike female menopause, which is abrupt and universal, male hormonal decline is gradual, highly individual, and not always clinically significant. Low testosterone must be confirmed biochemically and correlated with symptoms before therapy is considered.

This protocol provides a framework for evaluation and, where indicated, physician-directed testosterone replacement alongside adjunctive GH axis support and lifestyle optimization. It is not a recommendation to self-treat with testosterone obtained outside medical channels, which carries serious safety and legal risks.

Compounds Involved

Testosterone Therapy

Physiologic testosterone replacement — typically 80–160 mg/week split into 2 doses — produces trough-to-peak levels within or near the natural range. Supra-physiologic doses are anabolic androgenic steroid use, not replacement, and carry different risks.

HCG

HCG preserves testicular volume and spermatogenesis during TRT, which is relevant for men who want to preserve fertility or the option to come off therapy.

GH Secretagogues

Age-related GH decline ("somatopause") parallels testosterone decline. Low-dose Ipamorelin/CJC-1295 is adjunctive rather than essential — it tends to improve sleep and body composition at the margin.

PT-141

Libido does not always track with testosterone levels. PT-141 is available as an episodic tool for men whose desire remains problematic even on well-optimized TRT (see Libido Protocol).

Protocol Structure

Phase 1 — Evaluation (Weeks 1–4)

Confirm before treating.

• Two morning total testosterone measurements on separate days, with SHBG, free T (calculated or equilibrium dialysis), LH, FSH, prolactin, estradiol (sensitive assay), TSH
• General labs — CBC, CMP, lipid panel, HbA1c, PSA (age-appropriate), vitamin D, ferritin
• Contributors to low T — sleep apnea (extremely common and reversible), obesity, alcohol excess, opioid exposure, chronic stress, deficient training
• Lifestyle optimization first — addressing sleep, weight, training, and alcohol commonly raises testosterone 20–30% without pharmacology

If total T is clearly low (<300 ng/dL typically, thresholds vary) and symptoms correlate, proceed to medical evaluation for TRT.

Phase 2 — TRT Initiation (Weeks 4–12, Physician-Directed)

• Testosterone cypionate 80–100 mg/week, often split into 2x/week subcutaneous injections
• HCG 500 IU 2x/week if fertility preservation matters
• Baseline sensitive estradiol before considering anastrozole; many men do fine without it
• Repeat labs at 6–8 weeks: total and free T, estradiol, hematocrit, PSA if age-appropriate
• Adjust dose to target total T mid-to-upper normal range with symptom resolution

Phase 3 — Adjunctive Layer (Month 3 onward)

• Ipamorelin 200 mcg + CJC-1295 (no-DAC) 100 mcg subcutaneous pre-bed, 5 nights/week during 12-week blocks
• BPC-157 250 mcg/day during intense training blocks or for nagging tendon issues
• PT-141 1–1.5 mg pre-event as needed for libido gaps
• Continue vitamin D optimization, omega-3, resistance training, and adequate sleep

Phase 4 — Long-Term Monitoring

• Semiannual labs initially, then annual once stable: total / free T, estradiol, hematocrit, lipid panel, PSA (age-appropriate), HbA1c
• Hematocrit drift toward >52–54% warrants dose adjustment or therapeutic phlebotomy
• PSA trajectory matters more than single values; any acceleration requires urologic evaluation
• Cycle GH secretagogues: 12 weeks on, 4 weeks off

Important Considerations

• TRT is a medical therapy requiring ongoing clinician oversight. Self-administered testosterone from non-pharmaceutical sources carries meaningful risk (contamination, dosing errors) and legal exposure.
• Contraindications include active prostate or breast cancer, uncontrolled heart failure, severe untreated sleep apnea, and certain erythrocytosis conditions.
• TRT can modestly reduce fertility — men who may want children should consider HCG from the outset or bank sperm before initiating.
• Estradiol is important for male health; aggressive anastrozole dosing causes low-E2 symptoms (joint pain, low libido, mood disturbance) and is generally avoidable.
• Hematocrit rise is the most common TRT-related lab issue; hydration, subcutaneous (rather than IM) injection, and dose adjustments help.
• GH secretagogues can slightly reduce insulin sensitivity — monitor fasting glucose.
• "Feeling good" is not a substitute for labs. Men on TRT without regular monitoring are missing preventable problems.
• Stopping TRT without a structured taper / recovery plan can produce prolonged HPG suppression and symptomatic hypogonadism — see Tapering and Discontinuation.

Disclaimer

This content is for educational and informational purposes only and is not medical advice. Testosterone replacement therapy is a prescription medical treatment that requires diagnostic evaluation and ongoing management by a qualified clinician. HCG and aromatase inhibitors are prescription medications. The peptides referenced (Ipamorelin, CJC-1295, BPC-157, PT-141) are not FDA-approved for human use in the United States and are sold as research chemicals in most jurisdictions. Do not self-administer testosterone or related compounds outside of legitimate medical supervision. Pepperpedia does not endorse the acquisition or use of unapproved substances or the use of prescription hormones outside of physician-directed care.